1. Home
  2. ITRG vs CSTL Comparison

ITRG vs CSTL Comparison

Compare ITRG & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra Resources Corp.

ITRG

Integra Resources Corp.

HOLD

Current Price

$2.37

Market Cap

529.9M

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$22.20

Market Cap

640.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRG
CSTL
Founded
1997
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
529.9M
640.6M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
ITRG
CSTL
Price
$2.37
$22.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$5.13
$45.50
AVG Volume (30 Days)
3.6M
324.8K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
$67.34
$2.42
Revenue Next Year
$25.89
$12.69
P/E Ratio
$45.07
N/A
Revenue Growth
N/A
3.66
52 Week Low
$1.43
$14.59
52 Week High
$4.87
$44.28

Technical Indicators

Market Signals
Indicator
ITRG
CSTL
Relative Strength Index (RSI) 40.54 57.70
Support Level $2.32 $21.77
Resistance Level $3.29 $24.33
Average True Range (ATR) 0.15 0.85
MACD 0.01 0.23
Stochastic Oscillator 16.30 90.40

Price Performance

Historical Comparison
ITRG
CSTL

About ITRG Integra Resources Corp.

Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: